Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in children with Down syndrome-associated myeloid leukemia
NL-OMON55026Phase 3Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Started Sep 2022; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55026.